1-4 of 4
Wen Jiang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Cha Len Lee, Grainne M. O'Kane, Warren P. Mason, Wen-Jiang Zhang, Pavlina Spiliopoulou, Aaron R. Hansen, Robert C. Grant, Jennifer J. Knox, Tracy L. Stockley, Gelareh Zadeh, Eric X. Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 394–399.
https://doi.org/10.1158/1535-7163.MCT-23-0460
Published: 04 March 2024
View articletitled, Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma in another window
Journal Articles

Radiation Synergizes with IL2/IL15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity

Xuefeng Li, Kristin Huntoon, Yifan Wang, DaeYong Lee, Shiyan Dong, Abin Antony, Carl Walkey, Betty Y.S. Kim, Wen Jiang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 330–342.
https://doi.org/10.1158/1535-7163.MCT-23-0236
Published: 04 March 2024
View articletitled, Radiation Synergizes with IL2/IL15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity
Open the PDF for Radiation Synergizes with IL2/IL15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Albiruni RA Razak, Philippe L. Bedard, Benoit You, Devang Panchal, Eric X. Chen, S. Percy Ivy, Wen-Jiang Zhang, Suzanne Kamel-Reid, Nhu-An Pham, Tong Zhang, Sebastien J. Hotte, Michael Reedijk, Momiko Shimizu, Laurie Ailles, Christine Haines, Amit Oza, Ming Tsao, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B50.
https://doi.org/10.1158/1535-7163.TARG-11-B50
Published: 12 November 2011
View articletitled, Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
Journal Articles

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells

Sean C. Dowdy, Shujuan Jiang, X. Clare Zhou, Xiaonan Hou, Fan Jin, Karl C. Podratz, Shi-Wen Jiang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (11): 2767–2776.
https://doi.org/10.1158/1535-7163.MCT-06-0209
Published: 22 November 2006
View articletitled, Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells
Open the PDF for Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells in another window